Schering-Plough Merger Offers Merck OTC Business, Zegerid Switch Rights
This article was originally published in The Tan Sheet
Executive Summary
Merck stands to pick up the switch rights to the proton pump inhibitor Zegerid at the head of a strong switch program if its planned acquisition of Schering-Plough succeeds
You may also be interested in...
Merck Settles Class Suit Targeting Coppertone Claims, Denies Wrongdoing
Merck agrees to pay a maximum of $10 million to consumers to settle class-action case and to comply with labeling and claims regulations that will become law in December for most firms under an FDA final rule. The settlement in federal court resolves separate litigation against Coppertone filed in California state court.
Merck Looks To “Exploit” Switches With Exit From J&J Joint Venture
Merck gains flexibility to pursue Rx-to-OTC switches, such as allergy drug Clarinex and cholesterol treatment Zetia by exiting its OTC joint venture with Johnson & Johnson.
Merck Looks To “Exploit” Switches With Exit From J&J Joint Venture
Merck gains flexibility to pursue Rx-to-OTC switches, such as allergy drug Clarinex and cholesterol treatment Zetia by exiting its OTC joint venture with Johnson & Johnson.